Cargando…

Sars-CoV2 Antibody Responses in Patients with Hematological Malignancies Following Anti-CD20 Therapy

Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with increased mortality in patients with hematological malignancies, with increase rates between 33-37%. Vaccination against SARS-CoV-2 have shown efficacy decreasing infection rates, with efficacy ra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guerra, Veronica A, Ocampo, Marisol, Cusnir, Mike
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology. Published by Elsevier Inc. 2021
Materias:	623.Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701424/ http://dx.doi.org/10.1182/blood-2021-154090

Ejemplares similares

Serologic Responses Following Sars-Cov-2 Vaccination and Factors Influencing It in Patients with Hematological Malignant and Non-Malignant Diseases - a Prospective Multicentric Study
por: Sertić, Zrinka, et al.
Publicado: (2021)

Purine Analogues Increase the Risk of Lethal and/or Prolonged COVID19 While Obinutuzumab Increases the Risk of Prolonged but Not Lethal Infection in Patients Treated for Lymphoid Malignancies -a Study of Krohem, the Croatian Group for Hematologic Diseases
por: Aurer, Igor, et al.
Publicado: (2021)

Oral Ixazomib in Untreated Follicular Lymphoma Permits COVID-19 Vaccine Response and Its Efficacy Is Associated with Clinical Factors and Gene Expression Signatures
por: Graf, Solomon A., et al.
Publicado: (2021)

Efficacy of Vaccine BNT162b2 (Pfizer-BioNTech) in Individuals with Waldenstrom's Macroglobulinemia and Follicular Lymphoma in Australia
por: Beaton, Brendan, et al.
Publicado: (2021)

Global Waldenström's Macroglobulinemia Patient-Derived Data Registry, Whimsical, Highlights Real-World Treatment Outcomes and COVID-19 Data
por: Tohidi-Esfahani, Ibrahim, et al.
Publicado: (2021)

Characteristics and Outcomes of COVID-19 Patients with Mature B-Cell Non-Hodgkin Lymphomas (mB-Cell NHL): A US Nationwide Electronic Health Record (EHR) Database Study
por: Yue, Xiaomeng, et al.
Publicado: (2021)

IBCL-054 The Effects of an mRNA COVID-19 Vaccine Booster on Immune Responses in Cancer-Bearing Veterans
por: Frankel, Arthur, et al.
Publicado: (2022)

Follicular lymphoma
por: Leich, Ellen
Publicado: (2019)

ABCL-013: Factors Associated with SARS-CoV-2 Infection and Outcome in Patients with Solid Tumors or Hematological Malignancies: A Single-Center Study
por: Goudsmit, Anouk, et al.
Publicado: (2021)

Follicular lymphoma genomics
por: Kumar, Emil, et al.
Publicado: (2019)

Treatment of high-risk follicular lymphoma
por: Jurczak, Wojciech
Publicado: (2019)

Novel prognostic tools that identify high-risk follicular lymphoma
por: Luminari, Stefano
Publicado: (2019)

ABCL-274: Outcomes in Patients with Lymphoproliferative Diseases and COVID-19: Results of a Subgroup Analysis of the CHRONOS19 Registry
por: Gavrilina, Olga, et al.
Publicado: (2021)

ABCL-334: Impact of COVID-19 Pandemic on Treatment Duration in Curable Cancers: Comparison of Patients with DLBCL Treated Before and During: A Retrospective Record-Based Study
por: Anandaradje, Annuja, et al.
Publicado: (2021)

Large B-cell lymphomas
por: Vitolo, Umberto
Publicado: (2019)

ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers: The Israeli/Italian Study
por: Giladi, Odil, et al.
Publicado: (2022)

Impaired Sars-Cov-2 Specific Antibody Responses in Patients Treated with Anti-CD20 Antibodies
por: Sottini, Alessandra, et al.
Publicado: (2020)

A Rare Case of Primary Intracardiac Diffuse Large B-Cell Lymphoma: Multimodality Imaging to the Rescue
por: Gioia, Mario, et al.
Publicado: (2019)

Aggressive B-cell lymphoma subtyping: a pathologists viewpoint
por: de Jong, Daphne
Publicado: (2019)

Molecular classification of aggressive B-cell lymphoma
por: Bojarczuk, Kamil, et al.
Publicado: (2019)

Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells
por: Small, George W., et al.
Publicado: (2013)

Increase in Antibody Titers Following Sars-Cov-2 Vaccination Remains Limited for More Than 3 Years after Final Dose of Anti-CD20 Antibody
por: Funakoshi, Yohei, et al.
Publicado: (2021)

Using benchmarked lung radiation dose constraints to predict pneumonitis risk: Developing a nomogram for patients with mediastinal lymphoma
por: Pinnix, Chelsea C., et al.
Publicado: (2018)

Radiation Recall Dermatitis After the Use of Pralatrexate for Peripheral T-cell Lymphoma
por: Bhangoo, Ronik S., et al.
Publicado: (2018)

Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites?
por: Lee, Jessica W., et al.
Publicado: (2019)

Intrafractional Displacement of Cardiac Substructures Among Patients With Mediastinal Lymphoma or Lung Cancer
por: Guzhva, Lidia, et al.
Publicado: (2019)

Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy
por: Sheu, Tommy, et al.
Publicado: (2018)

Does the Incidence of Treatment-Related Toxicity Plateau After Radiation Therapy: The Long-Term Impact of Integral Dose in Hodgkin's Lymphoma Survivors
por: Holtzman, Adam L., et al.
Publicado: (2019)

Poster: ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers: The Israeli/Italian Study
por: Giladi, Odil, et al.
Publicado: (2022)

Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies
por: Fagnano, Ester, et al.
Publicado: (2023)

Safety and Efficacy of Sars-Cov-2 Vaccines in Hodgkin Lymphoma Patients Receiving PD-1 Inhibitors
por: Svoboda, Jakub, et al.
Publicado: (2021)

The Impact of the COVID-19 Pandemic on the Diagnosis and Management of Patients with Classical Hodgkin Lymphoma: A Single-Center Experience
por: Kucukyurt, Selin, et al.
Publicado: (2021)

Patients with Hodgkin Lymphoma Develop Adequate Humoral Serological Response to Vaccination with Two Doses of BNT162b2
por: Dann, Eldad J, et al.
Publicado: (2021)

Regulation of human T-cell leukemia virus type 1 antisense promoter by myocyte enhancer factor-2C in the context of adult T-cell leukemia and lymphoma
por: Madugula, Kiran K., et al.
Publicado: (2022)

Seroconversion Rates after COVID-19 Vaccination Amongst Patients with Hematologic Malignancies: Results of a Rapid Vaccination and Evaluation Program in a Minority Rich, Ethnically Diverse Inner City Cohort
por: Shapiro, Lauren C, et al.
Publicado: (2021)

Le syndrome post-COVID chez le personnel de santé dans un centre hospitalo-universitaire dans la région du centre tunisien
por: Chouchane, Asma, et al.
Publicado: (2022)

Targeting cell cycle regulators in hematologic malignancies
por: Aleem, Eiman, et al.
Publicado: (2015)

Factors Associated with Seroconversion after COVID-19 Vaccination in Patients with Hematologic Malignancies
por: Ollila, Thomas A., et al.
Publicado: (2021)

P2X7 Receptor in Hematological Malignancies
por: De Marchi, Elena, et al.
Publicado: (2021)

Outcomes of Patients of Eastern Mediterranean Region with Lymphoma and COVID-19.Does Recent Chemo Immunotherapy Have a Role on Severity?
por: Tailor, Imran K, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g3fgc5ubb3btjomhme5e67ge1d